Opinion

Video

Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections

Key Takeaways

  • Rebyota's FDA approval was based on clinical trial data showing significant reduction in CDI recurrence rates compared to placebo.
  • The pivotal trial was a randomized, double-blind, placebo-controlled study demonstrating Rebyota's efficacy in recurrent CDI.
SHOW MORE

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
4 experts in this video
4 experts in this video
Dr Caroline Vovan
1 expert is featured in this series.
1 expert is featured in this series.
Dr María Díez Campelo
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo